Daehan Nupharm

At a glance

Daehan Nupharm filed 29 disclosures in the last 12 months, including 7 5% holder and 2 insider. The most recent key filing was on Oct 1.

Revenue for 2025 was ₩202B, up 0.1% on 2024. Operating margin was 5.8% against 9.2% a year earlier. Debt was 94% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩111B and operating profit of ₩5.3B.

The 2025 annual report lists 393 employees with an average tenure of 6.8 years and average pay of ₩62.3M, #861 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩367.9M each on average. It paid ₩100 per common share in cash dividends, against ₩100 a year earlier (+0%). 이완진 and related parties held 40.50% at year end.

From the 2025 annual report

Staff: 393 (229 men, 164 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩24.5B. Directors and auditors: 4, paid ₩1.5B in total.

Dividends (common shares)

Largest shareholder

이완진 holds 26.53%; with 7 related parties the group holds 40.50% of common shares at year end (from 40.36% at the start of the year).

Auditor: 대주 회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary